Tag: Blood Disorders
Model Predicts Need for Bone Marrow Sampling in Monoclonal Gammopathy of Undetermined Significance
Model predicts smoldering multiple myeloma or worse among patients with monoclonal gammopathy of undetermined significance
Increased Morbidity Risks Seen for Male, Female p.C282Y Homozygotes
Increased risks seen for those with baseline hemochromatosis diagnoses and for those undiagnosed with hemochromatosis
Benralizumab Noninferior to Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis
Benralizumab is noninferior, but not superior, for adults with eosinophilic granulomatosis with polyangiitis receiving standard care
Rusfertide Treatment Beneficial for Patients With Polycythemia Vera
Rusfertide reduces number of phlebotomies and maintains hematocrit at less than 45 percent
Outcomes Similar for Therapy-Related, De Novo MDS After Haplo-HSCT
Three-year overall and disease-free survival, three-year cumulative incidence of relapse similar between the groups
Oral Switch Noninferior for Low-Risk S. Aureus Bloodstream Infection
Early oral antimicrobial therapy noninferior to intravenous standard therapy for low-risk bloodstream infection
FDA Approves Casgevy to Treat Beta-Thalassemia
Casgevy is the first CRISPR-based medicine to be approved for use in the United States
Imetelstat Leads to Durable Red Blood Cell Transfusion Independence
Findings seen in heavily transfused patients with lower-risk myelodysplastic syndromes
American Society of Hematology, Dec. 9 to 12
Hematocrit Within Normal Range With Testosterone Gender-Affirming Therapy
Mean hematocrit ranged from 41.84 to 45.68 percent for those receiving testosterone as gender-affirming hormone therapy
